병원 감염 치료제 시장 보고서 : 약제 유형, 적응증, 지역별(2025-2033년)

The global hospital infection therapeutics market size reached USD 13.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 19.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.32% during 2025-2033. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Trends:

Increasing incidence of hospital-acquired infections (HAIs):

One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.

Growing awareness of antimicrobial stewardship programs

Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.

Significant advancements in R&D activities

Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.

Rising healthcare expenditure and infrastructure development

The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.

Hospital Infection Therapeutics Industry Segmentation:

Breakup by Drug Type:

• Anti-bacterial Drugs
• Anti-fungal Drugs
• Anti-viral Drugs
• Others

Anti-bacterial drugs accounts for the majority of the market share

The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.

In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.

Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.

Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.

Breakup by Indication:

• Blood Stream Infections
• Urinary Tract Infections
• Surgical Site Infections
• Pneumonia
• Others

Surgical site infections holds the largest share of the industry

The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.

The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.

Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.

Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.

Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.

Moreover, North America's robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.

Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.

Besides this, Latin America's evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.

Leading Key Players in the Hospital Infection Therapeutics Industry:

The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Allergan Plc (AbbVie Inc.)
• AstraZeneca Plc
• Bayer Aktiengesellschaft
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co. Inc
• Pfizer Inc.
• Sanofi S.A.

Key Questions Answered in This Report:

• How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
• What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
• What are the key regional markets?
• Which countries represent the most attractive hospital infection therapeutics market?
• What is the breakup of the market based on the drug type?
• Which is the most attractive drug type in the hospital infection therapeutics market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the hospital infection therapeutics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global hospital infection therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Anti-bacterial Drugs
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Anti-fungal Drugs
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Anti-viral Drugs
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Blood Stream Infections
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Urinary Tract Infections
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Surgical Site Infections
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pneumonia
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Allergan Plc (AbbVie Inc.)
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 AstraZeneca Plc
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Bayer Aktiengesellschaft
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bristol-Myers Squibb Company
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 SWOT Analysis
  • 13.3.6 Gilead Sciences Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 GlaxoSmithKline Plc
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Johnson & Johnson
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Merck & Co. Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Pfizer Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Sanofi S.A.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis